These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 23581641)
61. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). Chen J; Kinoshita T; Gururaja T; Sukbuntherng J; James D; Lu D; Whang J; Versele M; Chang BY Eur J Haematol; 2018 Jul; ():. PubMed ID: 30030853 [TBL] [Abstract][Full Text] [Related]
62. Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology domain of mouse Btk. Kikuchi Y; Hirano M; Seto M; Takatsu K Int Immunol; 2000 Oct; 12(10):1397-408. PubMed ID: 11007757 [TBL] [Abstract][Full Text] [Related]
63. Bruton's tyrosine kinase: oncotarget in myeloma. Tai YT; Anderson KC Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914 [TBL] [Abstract][Full Text] [Related]
64. Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts. Joseph RE; Wales TE; Fulton DB; Engen JR; Andreotti AH Structure; 2017 Oct; 25(10):1481-1494.e4. PubMed ID: 28867612 [TBL] [Abstract][Full Text] [Related]
65. Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis. Nyhoff LE; Barron BL; Johnson EM; Bonami RH; Maseda D; Fensterheim BA; Han W; Blackwell TS; Crofford LJ; Kendall PL Arthritis Rheumatol; 2016 Aug; 68(8):1856-68. PubMed ID: 26945549 [TBL] [Abstract][Full Text] [Related]
66. Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases. Chopra N; Wales TE; Joseph RE; Boyken SE; Engen JR; Jernigan RL; Andreotti AH PLoS Comput Biol; 2016 Mar; 12(3):e1004826. PubMed ID: 27010561 [TBL] [Abstract][Full Text] [Related]
67. Physical mapping in the region of the Bruton's tyrosine kinase and alpha-galactosidase A gene loci in proximal Xq22. Sweatman AK; Bradley LA; Lovering RC; O'Reilly MA; Levinsky RJ; Kinnon C Hum Genet; 1994 Dec; 94(6):624-8. PubMed ID: 7989038 [TBL] [Abstract][Full Text] [Related]
68. Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Elbezanti WO; Al-Odat OS; Chitren R; Singh JK; Srivastava SK; Gowda K; Amin S; Robertson GP; Nemmara VV; Jonnalagadda SC; Budak-Alpdogan T; Pandey MK Front Pharmacol; 2022; 13():894535. PubMed ID: 36160379 [TBL] [Abstract][Full Text] [Related]
69. Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Lindvall JM; Blomberg KE; Wennborg A; Smith CI Cell Immunol; 2005 May; 235(1):46-55. PubMed ID: 16137664 [TBL] [Abstract][Full Text] [Related]
70. Expression of BTK/p-BTK is different between CD5 Duan N; Zhao M; Wang Y; Qu Y; Liu H; Wang H; Xing L; Shao Z Hematology; 2019 Dec; 24(1):588-595. PubMed ID: 31392938 [No Abstract] [Full Text] [Related]
71. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605 [TBL] [Abstract][Full Text] [Related]
72. Assessment of male CVID patients for mutations in the Btk gene: how many have been misdiagnosed? Weston SA; Prasad ML; Mullighan CG; Chapel H; Benson EM Clin Exp Immunol; 2001 Jun; 124(3):465-9. PubMed ID: 11472409 [TBL] [Abstract][Full Text] [Related]
73. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207 [TBL] [Abstract][Full Text] [Related]
74. Evolutionary relationship between the cysteine and histidine rich domains (CHORDs) and Btk-type zinc fingers. Kaur G; Subramanian S Bioinformatics; 2018 Jun; 34(12):1981-1985. PubMed ID: 29390068 [TBL] [Abstract][Full Text] [Related]
75. Bruton's tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response. Guan D; Wang Z; Huo J; Xu S; Lam KP Cell Death Dis; 2021 Apr; 12(5):431. PubMed ID: 33931590 [TBL] [Abstract][Full Text] [Related]
76. Identification and characterization of a homologue of Bruton's tyrosine kinase, a Tec kinase involved in B-cell development, in a modern representative of a phylogenetically ancient vertebrate. Haire RN; Strong SJ; Litman GW Immunogenetics; 1997; 46(4):349-51. PubMed ID: 9218539 [No Abstract] [Full Text] [Related]
77. Effects of BTK signalling in pathogenic microorganism infections. Ye B; Zhou C; Guo H; Zheng M J Cell Mol Med; 2019 Oct; 23(10):6522-6529. PubMed ID: 31397086 [TBL] [Abstract][Full Text] [Related]
78. Direct stimulation of Bruton's tyrosine kinase by G protein alpha subunits. Lowry WE; Ma YC; Cvejic S; Huang XY Methods Enzymol; 2002; 345():464-9. PubMed ID: 11665629 [No Abstract] [Full Text] [Related]
80. BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses. Althubiti M; Rada M; Samuel J; Escorsa JM; Najeeb H; Lee KG; Lam KP; Jones GD; Barlev NA; Macip S Cancer Res; 2016 Sep; 76(18):5405-14. PubMed ID: 27630139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]